Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

December 16, 2002 11:54 ET | Source: Actelion Ltd.

Actelion Nominates New Chief Financial Officer, Andrew J. Oakley, to succeed Andre J. Mueller effective January 2003; Mueller to concentrate on Actelion board mandate

ALLSCHWIL and BASEL, Switzerland, Dec. 16, 2002 (PRIMEZONE) -- Actelion Ltd (SWX: ATLN) (Other OTC:ALIOF) today announced that it has chosen Andrew J. Oakley (40) to succeed Andre J. Mueller (59) as...
November 26, 2002 03:56 ET | Source: Actelion Ltd.

Worldwide License Agreement Signed by OGS and Actelion -- Extension of European Partnership to All Territories (Excluding Israel)

ALLSCHWIL/BASEL ,Switzerland and OXFORD, U.K., Nov. 26, 2002 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) (Other OTC:ALIOF) and Oxford GlycoSciences Plc (LSE:OGS) (Nasdaq:OGSI) today announce that a...
November 26, 2002 03:41 ET | Source: Actelion Ltd.

Actelion Ltd.: European Commission Approval for Zavesca; European Launch of Type 1 Gaucher Treatment in spring 2003

ALLSCHWIL/BASEL, Switzerland and OXFORD, U.K., Nov. 26, 2002 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) and Oxford GlycoSciences Plc (LSE:OGS) (Nasdaq:OGSI) today announced that the...
November 26, 2002 03:28 ET | Source: Actelion Ltd.

Actelion Ltd.: Important Upcoming Corporate Calendar Dates

ALLSCHWIL, Switzerland, Nov. 26, 2002 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) would like to inform you of some important upcoming dates in 2003. January 23 What: Release of...
November 26, 2002 03:22 ET | Source: Actelion Ltd.

Actelion Ltd.: Invitation to Investor Conference Call/Webcast; Actelion to Discuss Enlarged Zavesca Partnership with Oxford Glycoscience Plc

ALLSCHWIL, Switzerland, Nov. 26, 2002 (PRIMEZONE) -- Actelion Ltd. (Other OTC:ALIOF): Dear Friend in the Investment Community: Actelion Ltd. has announced its enlarged Zavesca(TM) partnership...
November 05, 2002 02:01 ET | Source: Actelion Ltd.

Actelion Reports 3rd Quarter Results 2002; Tracleer Sales Momentum Confirmed; Company Increases Full-Year Sales Guidance by 15 percent to Between CHF 115 and 120 Million; Quarterly Net Loss Reduced by 42 percent

ALLSCHWIL/BASEL, Switzerland, Nov. 5, 2002 (PRIMEZONE) -- Actelion Ltd. (Other OTC:ALIOF) (SWX:ATLN) today reported results for the 3rd quarter 2002. Total operating revenues for Q3 2002 were CHF...
October 29, 2002 01:54 ET | Source: Actelion Ltd.

Actelion Ltd.: Successful Prevention Study with Tracleer in Scleroderma-Related Digital Ulcerations -- Presented at the American College of Rheumatology

ALLSCHWIL, Switzerland, Oct. 29, 2002 (PRIMEZONE) -- Actelion Ltd. (SWX:ATLN) (Other OTC:ALIOF) announced that Joseph H. Korn, MD, Professor of Medicine and Biochemistry, School of Medicine, Boston...
September 12, 2002 01:57 ET | Source: Actelion Ltd.

Actelion to Initiate Registration Study with Veletri in Acute Heart Failure; Successful Dose-Optimization Study

ALLSCHWIL and BASEL, Switzerland, Sept. 12, 2002 (PRIMEZONE) -- Actelion Ltd. today announced initial positive results from a dose-optimization study evaluating Veletri(TM) (tezosentan), an...
August 27, 2002 01:49 ET | Source: Actelion Ltd.

Actelion to List on SWX Main Market on September 9, 2002; Trading Symbol ATLN Remains Unchanged; Full Quarterly Reporting to Continue

ALLSCHWIL, Switzerland, Aug. 27, 2002 (PRIMEZONE) -- Actelion (SWX:ATLN) announced today that company's bearer shares will list be listed on the SWX Main Market board as of Monday, September 9,...
August 15, 2002 01:53 ET | Source: Actelion Ltd.

Actelion Reports Positive RAPIDS-1 Results; Actelion Reports Highly Significant Study Results With Tracleer in Digital Ulcers

ALLSCHWIL/BASEL, Switzerland, Aug. 15, 2002 (PRIMEZONE) -- Actelion Ltd (SWX:ATLN) announced today preliminary results from RAPIDS-1, evaluating the efficacy and safety of Tracleer(TM) in the...